NCT02312622 - Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

September 8, 2018

Study Completion Date

July 31, 2019

Conditions

Stage IV Non-small Cell Lung Cancer (NSCLC)Recurrent Non-small Cell Lung Cancer (NSCLC)Extensive-stage Small Cell Lung Cancer (SCLC)Recurrent Small Cell Lung Cancer (SCLC)Tumors Metastatic to BrainMetastatic Breast Cancer (mBC)

Interventions

DRUG

Pegylated Irinotecan

Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle)

Trial Locations (1)

94305

Stanford University, School of Medicine, Stanford